Seaport Therapeutics, Inc. (SPTX)
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Seaport Therapeutics, Inc. Common Stock
No splits on record
Nothing in SPTX's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Revenue | $0 |
| YoY Growth | - |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Gross Margin | - |
| Research and Development | $66.31M |
| Selling, General, and Administrative | $20.98M |
| Other | $0 |
| Total Operating Expenses | $87.29M |
| Operating Income (EBIT) | -$87.29M |
| Operating Margin | - |
| Interest Expense | $0 |
| Interest Income | $11.4M |
| Other Income (Expense) | $13.19M |
| Income Before Tax (EBT) | -$74.11M |
| Income Tax Expense | $773K |
| Net Income | -$74.88M |
| Net Income Margin | - |
| Supplementary Data | |
| EPS | -1.94 |
| Diluted EPS | -1.94 |
| Weighted Average OS | 38.65M |
| EBITDA | -$85.89M |
| EBITDA Margin | - |
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Assets | |
| Current Assets | |
| Cash and Cash Equivalents | $46.04M |
| Short-Term Investments | $169.94M |
| Cash and Short-Term Investments | $215.98M |
| Accounts Receivable | $3.03M |
| Inventory | $0 |
| Other Current Assets | $0 |
| Total Current Assets | $223.23M |
| Long-Term Assets | |
| Property, Plant & Equipment Net | $5.22M |
| Goodwill | $0 |
| Intangible Assets | $0 |
| Long-Term Investments | $17.67M |
| Deferred Tax Assets | $0 |
| Other Long-Term Assets | $2.88M |
| Total Long-Term Assets | $25.78M |
| Other Assets | $0 |
| Total Assets | $249.01M |
| Liabilities | |
| Current Liabilities | |
| Accounts Payable | $2.01M |
| Short-Term Debt | $0 |
| Current Income Tax Payable | $0 |
| Current Unearned Revenue | $0 |
| Other Current Liabilities | $5.19M |
| Total Current Liabilities | $12.78M |
| Long-Term Liabilities | |
| Long-Term Debt | $0 |
| Long-Term Unearned Revenue | $0 |
| Long-Term Deferred Tax Liabilities | $0 |
| Other Long-Term Liabilities | $325.33M |
| Total Long-Term Liabilities | $328.77M |
| Other Liabilities | $0 |
| Total Liabilities | $341.55M |
| Stockholders' Equity | |
| Preferred Stock | $0 |
| Common Stock | $1K |
| Retained Earnings | -$114.11M |
| Comprehensive Income & Other | $301K |
| Other Stockholders' Equity | $21.56M |
| Total Equity | -$92.55M |
| Minority Interest | $0 |
| Total Liabilities and Equity | $249.01M |
| Supplementary Data | |
| Total Debt | $5.08M |
| Net Debt | -$40.96M |
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Operating Activities | |
| Net Income | -$74.88M |
| Depreciation & Amortization | $1.41M |
| Deferred Income Tax | $0 |
| Stock-Based Compensation | $6.88M |
| Changes in Working Capital: | |
| Accounts Receivable | $0 |
| Inventory | $0 |
| Accounts Payable | -$2.73M |
| Other Working Capital | -$5.2M |
| Total Working Capital Change | -$7.93M |
| Other Non-Cash Items | -$3.42M |
| Net Cash from Operating | -$77.94M |
| Investing Activities | |
| Capital Expenditures | -$356K |
| Acquisitions | $0 |
| Purchases of Investments | -$396.39M |
| Sales of Investments | $212.5M |
| Other Investing Activities | $0 |
| Net Cash from Investing | -$184.25M |
| Financing Activities | |
| Debt Repaid | - |
| Common Stock Issuance | $1K |
| Common Stock Repurchases | $0 |
| Dividends Paid | $0 |
| Other Financing Activities | -$874K |
| Net Cash from Financing | -$873K |
| Forex Effect | $3K |
| Net Change in Cash | -$263.06M |
| Supplementary Data | |
| Operating Cash Flow | -$77.94M |
| Capital Expenditure | -$356K |
| Free Cash Flow | -$78.3M |
| Cash at Beginning | $309.55M |
| Cash at End | $46.5M |